Is AstraZeneca the Top Defensive Healthcare Play in 2026?

Why Is LSE:AZN - AstraZeneca Stock Rising 3.4% Today in March 2026?

Ankur Sharma | 30 March 2026

Why Are Investors Dumping Trellus Health Stock?

The stock’s movement underscores the high-risk nature of early-stage healthcare technology companies, where valuation is often heavily influenced by cash runway and financing developments.

Ankur Sharma | 30 March 2026

What’s Driving AstraZeneca Share Price Trends?

AstraZeneca plc(LSE:AZN) delivered a watershed moment for its pharmaceutical pipeline on March 27, 2026, announcing that tozorakimab met its primary efficacy and safety endpoints in two pivotal Phase III trials—OBERON and TITANIA—for respiratory disease treatment. This breakthrough marks a critical inflection point for the …

Ankur Sharma | 27 March 2026

What’s Dragging Oxford Biomedica Shares Lower Today?

Key Reasons Behind Today’s Decline

Ankur Sharma | 27 March 2026

Can LSE:PBX Sustain Its Rally Amid Iran War and Market Volatility?

What is driving ProBiotix Health (LSE:PBX) stock higher today?

Ankur Sharma | 27 March 2026

Can SkinBioTherapeutics Continue Its Explosive Growth in 2026?

Why Is LSE:SBTX – SkinBioTherapeutics Stock Surging 12.5% Today in March 2026?

Ankur Jaiswal | 27 March 2026

Why are biotech stocks like LSE:ONT down today amid Iran war fears?

Why is LSE:ONT - Oxford Nanopore Technologies stock falling today despite strong genomics demand?

Ankur Sharma | 26 March 2026

Is Cizzle Biotechnology a High-Growth Biotech Play?

Key HighlightsCIZ stock declines 16.96% to 2.33 GBX despite significant commercialization progress including secured $3.5M guaranteed royalties from US partnerCompany's CIZ1B biomarker test demonstrates 95% sensitivity for Stage I lung cancer detection with 96% negative predictive valueCizzle Bio Inc (US partner) in final stages …

Ankur Sharma | 25 March 2026

Is CRISM Therapeutics a High-Growth Biotech Play?

Key HighlightsLSE:CRTX stock declines 21.57% to 10.0 GBX amid broader biotech sector weakness affecting clinical-stage oncology companiesCRISM Therapeuticsreceived FDA Orphan Drug Designation for irinotecan-ChemoSeed in malignant glioma, validating core technologyCompany's lead asset ChemoSeed represents innovative biodegradable implantable drug delivery system addressing unmet cancer treatment …

Ankur Sharma | 25 March 2026

What’s Fueling the Rally in This Small-Cap Biotech Stock?

Ankur Sharma | 25 March 2026

Healthcare

Is AstraZeneca the Top Defensive Healthcare Play in 2026?

Why Are Investors Dumping Trellus Health Stock?

What’s Driving AstraZeneca Share Price Trends?

What’s Dragging Oxford Biomedica Shares Lower Today?

Can LSE:PBX Sustain Its Rally Amid Iran War and Market Volatility?

Can SkinBioTherapeutics Continue Its Explosive Growth in 2026?

Why are biotech stocks like LSE:ONT down today amid Iran war fears?

Is Cizzle Biotechnology a High-Growth Biotech Play?

Is CRISM Therapeutics a High-Growth Biotech Play?

What’s Fueling the Rally in This Small-Cap Biotech Stock?

Latest News

Is LSE:IOF One Of The Strongest Commodity-Linked Growth Stories On AIM?

Can Pantheon Resources Deliver on Its Alaska Oil Potential?

Is Altona Rare Earths a Hidden Rare Earth Opportunity?

Are UK Industrial Stocks Like Castings Undervalued?

How Does Market Volatility Affect CMCX Revenue?

Can Nanoco Survive as a Microcap Technology Stock?